ASTX727 in Patients with Hepatic Impairment
A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients With Moderate and Severe Hepatic Impairment
Arms / Cohorts
Experimental:Group B: Moderate hepatic impairment
Not yet accepting
Experimental:Group C: Severe hepatic impairment
Not yet accepting
Active Comparator:Group A: Normal hepatic function
Not yet accepting
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.